CogState Ltd
ASX:CGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CogState Ltd
Cash
CogState Ltd
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CogState Ltd
ASX:CGS
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
4DMedical Ltd
ASX:4DX
|
Cash
AU$56.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Pro Medicus Ltd
ASX:PME
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Cash
AU$14.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Artrya Ltd
ASX:AYA
|
Cash
AU$11.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
B
|
BlinkLab Ltd
ASX:BB1
|
Cash
AU$1.7m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CogState Ltd
Glance View
Cogstate Ltd. is a global cognitive science company. The firm provides computerized cognitive tests across various domains and support electronic clinical outcome assessment (eCOA) solutions. The firm's segment includes Clinical trials, Healthcare and Research. In the Clinical trials segment, the Company's technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians to assess cognitive decline. Research segment offers various research studies and academic collaborations across various indication of diseases.
